CeNes Limited And Tripos (TRPS) Announce Advancement In COMT Inhibitor Discovery Program
10/19/2005 5:12:50 PM
CAMBRIDGE, U.K., & ST. LOUIS--(BUSINESS WIRE)--April 14, 2005--CeNeS Pharmaceuticals plc (AIM:CEN), the Cambridge-based biopharmaceutical company, and Tripos, Inc. (Nasdaq:TRPS), a leading provider of drug discovery informatics products and chemistry research, today announced that they have reached important milestones in their joint research partnership on COMT inhibitors and have consequently entered into a new agreement to continue their collaboration. Terms of the agreement were not disclosed.
Following CeNeS' innovative research program that commenced in 2003, the two companies have been working together and have identified several series of novel compounds active against the clinically validated target catechol-O-methyltransferase (COMT).
comments powered by